Trial Profile
Validation of ERTugliflozin for Inhibiting Cardiac Fibrosis Using Cardiac MRI and Laboratory Parameters in Korean Heart Failure Patients With Nonischemic Cardiomyopathy(VERTICAL)
Status:
Not yet recruiting
Phase of Trial:
Phase III
Latest Information Update: 06 Dec 2022
Price :
$35
*
At a glance
- Drugs Ertugliflozin (Primary)
- Indications Cardiomyopathies; Heart failure
- Focus Therapeutic Use
- Acronyms VERTICAL
- 05 Aug 2020 New trial record